- Home
- TOVX vs PTIX Comparison
TOVX vs PTIX Comparison
Compare TOVX & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- PTIX
- Stock Information
- Founded
- TOVX 2001
- PTIX 1994
- Country
- TOVX United States
- PTIX United States
- Employees
- TOVX N/A
- PTIX N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- PTIX Health Care
- Exchange
- TOVX Nasdaq
- PTIX Nasdaq
- Market Cap
- TOVX 3.8M
- PTIX 3.3M
- IPO Year
- TOVX 2006
- PTIX 2016
- Fundamental
- Price
- TOVX $0.50
- PTIX $3.69
- Analyst Decision
- TOVX Hold
- PTIX
- Analyst Count
- TOVX 1
- PTIX 0
- Target Price
- TOVX N/A
- PTIX N/A
- AVG Volume (30 Days)
- TOVX 170.1K
- PTIX 188.8K
- Earning Date
- TOVX 08-12-2025
- PTIX 08-13-2025
- Dividend Yield
- TOVX N/A
- PTIX N/A
- EPS Growth
- TOVX N/A
- PTIX N/A
- EPS
- TOVX N/A
- PTIX N/A
- Revenue
- TOVX N/A
- PTIX N/A
- Revenue This Year
- TOVX N/A
- PTIX N/A
- Revenue Next Year
- TOVX N/A
- PTIX N/A
- P/E Ratio
- TOVX N/A
- PTIX N/A
- Revenue Growth
- TOVX N/A
- PTIX N/A
- 52 Week Low
- TOVX $0.40
- PTIX $2.35
- 52 Week High
- TOVX $7.37
- PTIX $15.54
- Technical
- Relative Strength Index (RSI)
- TOVX 45.57
- PTIX 50.25
- Support Level
- TOVX $0.42
- PTIX $3.28
- Resistance Level
- TOVX $0.48
- PTIX $4.04
- Average True Range (ATR)
- TOVX 0.03
- PTIX 0.29
- MACD
- TOVX 0.02
- PTIX 0.03
- Stochastic Oscillator
- TOVX 88.67
- PTIX 45.05
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.